

EVOTEC AG

ISIN: DE0005664809 WKN: 566480 Asset Class: Stock

Company 2024/06/04 15:01:54

Price
8.89 EUR

Difference ▼ -1.66% (-0.15)



Contact Details

EVOTEC SE Tel: +49-40-56081-0
 -- Fax: +49-40-56081-222
 Manfred Eigen Campus, Essener Web: <http://evotec.com>
 Bogen 7 E-mail: info@evotec.com
 22419 Hamburg

Company Profile

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	903,162,000		1,073,671,000		1,100,940,000	
Common stock capital		177,186,000		176,953,000		176,608,000
Fixed assets	1,395,891,000		1,232,464,000		1,175,323,000	
Equity capital of a company		1,119,908,000		1,187,184,000		1,377,685,000
Cash and cash equivalents	510,909,000		415,155,000		699,326,000	
Accrued liabilities		16,062,000		16,427,000		18,021,000
Other assets	-		-		-	
Current liabilities		464,573,000		337,706,000		324,516,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		714,572,000		781,245,000		574,062,000
Different income		-		-		-
Other liabilities		156,676,000		207,113,000		34,943,000
Total assets	2,299,053,000	2,299,053,000	2,306,135,000	2,306,135,000	2,276,263,000	2,276,263,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	5,000	4,952	4,198
Equity ratio	48.71%	51.48%	60.52%
Debt-equity ratio	105.29%	94.25%	65.22%

Others

	2023	2022	2021
Tax Expense Rate	39.18%	11.72%	-4.75%

Income statement

	2023	2022	2021
Turnover	781,426,000	751,448,000	618,034,000
Net income	-83,913,000	-175,655,000	215,510,000
EBIT	-101,365,000	-176,079,000	228,532,000
Operating income before taxes	-103,841,000	-180,893,000	221,550,000
Cash Flow	33,951,000	203,106,000	122,237,000
Net interest income	-2,476,000	-4,814,000	-6,982,000
Research and development expenses	112,529,000	76,642,000	72,200,000
Income taxes	-40,680,000	-21,202,000	-10,530,000
Result from investments in subsidiaries, associates and other	-20,752,000	-15,964,000	-16,570,000
Revenues per employee	156,285	151,746	147,221

Board of Directors

Iris Löw-Friedrich	Chairman of Supervisory Board
Constanze Ulmer-Eilfort	Member of Supervisory Board
Elaine Sullivan	Member of Supervisory Board
Camilla Languille	Member of Supervisory Board
Roland Sackers	Member of Supervisory Board

Members of Management Board

Mario Polywka	Chairman of Managing Board
Cord Dohrmann	Member of Executive Committee
Craig Johnstone	Member of Executive Committee
Matthias Evers	Member of Executive Committee
Laetitia Rouxel	Member of Executive Committee